Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, Cristofanilli M, Platanias LC, Giles FJ. Chae YK, et al. Oncotarget. 2016 Oct 4;7(40):65364-65373. doi: 10.18632/oncotarget.11692. Oncotarget. 2016. PMID: 27588476 Free PMC article.
Sixty-five genes were common to both assays. Concordance was defined as the presence or absence of the identical genomic alteration(s) in a single gene on both molecular platforms. ...When eliminating alterations not detectable in the cfDNA assay, mean number of alteration …
Sixty-five genes were common to both assays. Concordance was defined as the presence or absence of the identical genomic alteration(s …
Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.
Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ. Costa R, et al. Oncotarget. 2017 Jun 29;8(40):67782-67789. doi: 10.18632/oncotarget.18847. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978071 Free PMC article.
There is positive correlation between phase 1 trial sample size and concordance of toxicity frequencies seen in late-phase studies. In conclusion, current immunotherapy phase 1 trials are appropriate in assessing safety profile of anti-PD-1 and PD-L1 antibodies....
There is positive correlation between phase 1 trial sample size and concordance of toxicity frequencies seen in late-phase studies. I …